Synexus recruits and treats patients in clinical trials, supporting late-stage drug research.

It has grown to become one of the largest clinical trial research site groups in the world.

The company operates from 24 sites in eight countries

Woman lying down for CT scan
We have worked with Synexus to expand its international capabilities and broaden its service portfolio


Regulatory drivers and a focus on efficiency throughout the drug development process has created demand for cost-effective pharmaceutical trials, which can reach out to many patients quickly and deliver consistent, high-quality clinical outcomes.


In order to build a global, market-leading business, we developed a strategy with management that focuses on:

“The company’s excellent progress is directly related to putting in place a team and operational structure with expanded best-in-class capacity that deliver for clients and the business alike.” Andrew Aylwin, Partner at Lyceum Capital and board member at Synexus


With our support Synexus has: